Johnson & Johnson says CARVYKTI delivered five-year remissions
Johnson & Johnson said a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.